This study describes a method for the radiolabeling of dextran with rhenium
-188 (Re-188). In nuclear oncology Re-188 is very useful for therapeutic ap
plications. Its nuclear characteristics allow radiotherapy and in situ moni
toring of tumor uptake as well as dosimetry calculations. Consequently new
compounds with this radiolabel are of general interest. Dextran was oxidize
d with sodium periodate yielding reactive aldehyde groups and subsequently
reacted with cysteine. The linkage was stabilized by reducing the Schiff ba
ses with sodium cyanoborohydride. The conjugate was then radiolabeled with
Re-188 by using Re-188-gluconate as the transchelator, labeling the free th
iols. Synthesis and radiolabeling were done in the absence of oxygen. The l
abeling efficiency was 60-70% and the radiochemical purity >95%. The in vit
ro stability study, using "cysteine challenge" demonstrated that 50% of the
radiolabel was transcomplexed to the 100 mM cysteine solution (after 1 h i
ncubation at 37 degrees C). However, at physiologic conditions and presence
of an antioxidant good stability was achieved. The Re-188 labeled dextran
presented in this study provides a template with therapeutic and diagnostic
potential in nuclear oncology, either alone for local treatment or as a ba
ckbone in a tumor specific conjugate for systemic treatment. (C) 2000 Elsev
ier Science Ltd. All rights reserved.